Egfrbi-Armed Autologous T Cells
Adult Brain Glioblastoma
Barbara Ann Karmanos Cancer InstituteCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Adult Brain Glioblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Temsirolimus University Hospital Heidelberg | Phase 2 | BBB |
Cediranib Lawrence Recht | Phase 2 | BBB |
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- National Cancer Institute (NCI) | Phase 2 | BB |
Irinotecan NaviFUS Corporation | Phase 3 | BB |
Gefetinib National Cancer Institute (NCI) | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Egfrbi-Armed Autologous T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →